Seok Joo Lee – CEO, ISU Abxis, South Korea
ISU Abxis, a subsidiary of the ISU conglomerate, is a biotech company with a focus on orphan drugs and rare disease. CEO Seok Joo Lee explains the rationale behind his…
The European Chamber of Commerce in Korea (ECCK) is the pre-eminent association of European companies conducting business in or related to Korea. Representing the common voice of the European business community in Korea, the ECCK aims to function as the platform for information exchange, effective communication channel to the Korean authorities and convenor of networking opportunities for European businesses. The ECCK is a non-profit and non-political organisation.
The ECCK was officially founded on 3 December 2012, upon the approval of the Ministry of Knowledge Economy (Ministry of Trade, Industry and Energy as of 2013). With its clear legal status defined under Korea’s Chamber of Commerce and Industry Act of 2008, the ECCK has focused on transparency and co-operation as its fundamental values.
The ECCK maintains its open door policy of actively listening to members’ opinions and suggestions in developing its programmes and activities. The ECCK seeks for collaboration with national chambers of commerce and European business associations to identify issues of common concern and effectively represent the interests of the European business community.
The ECCK is a strong believer in mutual prosperity. The ECCK hopes to contribute to fostering an optimal business climate for both European and local Korean companies. Moreover, as a good corporate citizen, the ECCK is determined to develop and carry out activities for the benefit of the Korean society.
The organisation is governed by the Board of Directors, entrusted with members’ mandate. The Advisory Board, comprised of national chambers and embassies, provides guidance and advice in regard to direction and activities. The Secretariat manages daily operation and activities of the Chamber.
Address
5F, Seoul Square, 416 Hangang-daero, Jung-gu,
Seoul 100-714, Korea
서울특별시중구한강대로 416 서울스퀘어 5층
(우 100-714)
Tel +82 2 6261 2700
Fax +82 2 6261 2730
E-mail ecck@ecck.eu
ISU Abxis, a subsidiary of the ISU conglomerate, is a biotech company with a focus on orphan drugs and rare disease. CEO Seok Joo Lee explains the rationale behind his…
Looking at what it takes to be a country manager of a multinational pharma company in some of the world’s most challenging markets. DHR International’s Helen Park outlines what she…
Syneos Health, established through a merger in 2017, has held a foothold in Korea through its legacy organisations for over 10 years. Sora Lee, general manager of Syneos Korea, provides…
SK Group, the second largest conglomerate in South Korea and renowned as a leader in energy, telecommunications, and the semiconductor business, entered drug development in 1993. In an exclusive interview,…
Bong Gil Nam, chairman and owner of Pharmbio Korea, offers his insights on his company’s importance in differentiating itself from the generic competitors in the market. Mr Nam also explains…
Bioneer, founded in 1992, lays claim to be Korea’s oldest biotechnology company. President, founder and CEO, Dr Han-Oh Park introduces the technological advances they have developed in molecular research tools,…
The Korea Drug Development Fund (KDDF) is a government-funded organization created to accelerate innovation activities in the Korean life sciences sector. In this interview, Samuel Muk explains how he integrated…
Dr Nam Han Cho, president of the International Diabetes Federation (IDF) and professor of Preventive Medicine at the Ajou University School of Medicine in South Korea is taking stock of his…
This week, the Korean Ministry of Food and Drug Safety announced that it would enhance drug safety management and make a new, streamlined review process for advanced healthcare goods. The…
The administration of President Moon Jae-in is moving to ensure the enduring success of South Korea’s healthcare and life sciences industries through increased international collaboration. However, some pharma insiders are…
Narihiko Yoshii, president of Mitsubishi Tanabe Pharma Korea unveils the value that they are bringing to Korean patients by utilising legislation regarding orphan drugs to fast track the market entry…
It was less than a decade ago (2011) that Samsung Biologics was a new kid on the block amongst Korea’s booming biotech conglomerates. Since then the company has snowballed, building…
See our Cookie Privacy Policy Here
